Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated ...

Greenwich LifeSciences, Inc.: Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...
Le Lézard

Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that, subject to the closing of its strategic partnership with Sobi, it plans to initiate the ...
EDN

Component and layout rules for USB-C, PD, and CMTI

Here are the essential design clues regarding USB component choices, layout constraints, and rule-of-thumb design practices.